Long-term safety of danicamtiv for genetic dilated cardiomyopathy
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the 24 weeks of treatment in the earlier DAN-301 study.
- If you are sexually active, you must agree to use highly effective birth control during the study and for 3 months after the last dose.
- You must be willing and able to follow the study procedures and give your written consent.
- You must not have had a heart attack, significant heart vessel blockage, or heart surgery within the last 90 days.
- You must not have been hospitalized for heart failure or needed IV diuretics within the last 90 days.
- You must not have had a stroke or other major cardiovascular event within the last 90 days.
- You must not have had a severe infection or sepsis within the last 30 days.
- You must not have a cancer that requires treatment and could affect your survival.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
This trial tests whether candesartan (a blood-pressure medicine) can delay or prevent heart muscle weakening in people who carry a disease-causing dilated cardiomyopathy gene variant but still have fairly strong heart pumping. Participants are randomly assigned to candesartan or a placebo to see which one keeps the heart healthier over time.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This trial tests whether combining modern heart failure medications with an implantable defibrillator (ICD) can reduce the risk of dangerous heart rhythms and improve survival in people with dilated cardiomyopathy. It focuses on those with a weak heart pump and specific scarring seen on MRI.
Hear when a new Symptomatic Genetic Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.